Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group
1996

Rhizoxin for Non-Small-Cell Lung Cancer

Sample size: 31 publication Evidence: moderate

Author Information

Author(s): S Kaplan, AR Hanauske, N Pavlidis, U Bruntsch, A te Velde, J Wanders, B Heinrich, J Verweij

Hypothesis

Does rhizoxin show activity in patients with advanced non-small-cell lung cancer?

Conclusion

Rhizoxin as a single agent shows activity in patients with advanced non-small-cell lung cancer.

Supporting Evidence

  • Four partial responses were observed in 27 evaluable patients.
  • Thirteen patients showed stabilization of their disease.
  • The median duration of response was 7 months.
  • The median survival from the start of treatment was 6 months.

Takeaway

Rhizoxin is a new medicine that helps some people with lung cancer feel better and live longer.

Methodology

A multicentre phase II trial was conducted with 31 chemotherapy-naive patients treated with rhizoxin.

Limitations

The study had a small sample size and did not include weekly laboratory tests for toxicity.

Participant Demographics

Patients were aged 27 to 76, with a mix of male and female participants.

Statistical Information

Confidence Interval

95% CI 4.2-33.7%

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication